Payment overview · 2025
General Payments
$1,787.81
72 reported records · 20 companies
Healthcare provider profile · identity verified
Priti Bhardwaj, MD
Allopathic & Osteopathic Physicians|Internal Medicine · TAYLOR, MI · NPI 1205879434
Verified facts
What the public records show
CMS Open Payments records show Priti Bhardwaj, MD received $1,787.81 in general payments during 2025 across 72 reported records.
AstraZeneca Pharmaceuticals LP accounted for 26.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Entresto, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Synthroid by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Zenpep by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 177 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 611 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $464.16 | 26.0% | 16 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $179.87 | 10.1% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $167.71 | 9.4% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $114.55 | 6.4% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $112.21 | 6.3% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $102.27 | 5.7% | 6 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $93.06 | 5.2% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $88.51 | 5.0% | 5 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $74.42 | 4.2% | 3 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $67.31 | 3.8% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $53.67 | 3.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $48.11 | 2.7% | 3 | 2025 |
| Orexo US, Inc. | Unresolved — no canonical attribution shown | $43.74 | 2.5% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $42.30 | 2.4% | 2 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $37.05 | 2.1% | 2 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $29.08 | 1.6% | 1 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$23.82 | 1.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.66 | 0.9% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $15.74 | 0.9% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $13.57 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,787.81 | 72 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $208.88 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $167.71 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $124.31 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $114.55 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $114.55 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $112.21 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $102.27 | 6 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $93.06 | 5 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $74.42 | 3 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $67.31 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $55.56 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $53.67 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $49.87 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $48.82 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $48.11 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $48.11 | 3 | 2025 |
Source payment records
|
|||||
| Zubsolv Normalized: zubsolv |
Drug | Orexo US, Inc. | $43.74 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $42.30 | 2 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $37.05 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $34.12 | 2 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $29.08 | 1 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $23.82 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $23.00 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.34 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $16.69 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.66 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $13.57 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $13.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ENTRESTO entresto |
2025 | Entresto | 2024 | 104 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 177 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 49 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 126 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
103 | 28 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
42 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
126 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
177 | 43 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
81 | 12 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
104 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
49 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
611 | 158 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1543 | 389 |
| Amlodipine Besylate | Amlodipine Besylate | 898 | 237 |
| Furosemide | Furosemide | 898 | 234 |
| Levothyroxine Sodium | Levothyroxine Sodium | 810 | 204 |
| Quetiapine Fumarate | Quetiapine Fumarate | 698 | 135 |
| Omeprazole | Omeprazole | 662 | 179 |
| Eliquis | Apixaban | 611 | 158 |
| Lisinopril | Lisinopril | 606 | 159 |
| Potassium Chloride | Potassium Chloride | 591 | 156 |
| Metoprolol Tartrate | Metoprolol Tartrate | 556 | 145 |
| Pantoprazole Sodium | Pantoprazole Sodium | 556 | 148 |
| Donepezil Hcl | Donepezil Hcl | 551 | 111 |
| Trazodone Hcl | Trazodone Hcl | 509 | 126 |
| Losartan Potassium | Losartan Potassium | 507 | 143 |
| Metformin Hcl | Metformin Hcl | 506 | 127 |
| Tamsulosin Hcl | Tamsulosin Hcl | 448 | 115 |
| Gabapentin | Gabapentin | 420 | 102 |
| Sertraline Hcl | Sertraline Hcl | 416 | 91 |
| Memantine Hcl | Memantine Hcl | 395 | 79 |
| Metoprolol Succinate | Metoprolol Succinate | 376 | 115 |
| Mirtazapine | Mirtazapine | 355 | 76 |
| Famotidine | Famotidine | 354 | 83 |
| Escitalopram Oxalate | Escitalopram Oxalate | 345 | 74 |
| Carvedilol | Carvedilol | 333 | 89 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 297 | 121 |
| Simvastatin | Simvastatin | 291 | 86 |
| Clopidogrel | Clopidogrel Bisulfate | 271 | 84 |
| Ibuprofen | Ibuprofen | 267 | 79 |
| Hydralazine Hcl | Hydralazine Hcl | 255 | 65 |
| Azithromycin | Azithromycin | 250 | 171 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 230 | 146 |
| Fluticasone Propionate | Fluticasone Propionate | 223 | 88 |
| Duloxetine Hcl | Duloxetine Hcl | 204 | 51 |
| Montelukast Sodium | Montelukast Sodium | 204 | 45 |
| Lorazepam | Lorazepam | 201 | 63 |
| Meloxicam | Meloxicam | 195 | 54 |
| Buspirone Hcl | Buspirone Hcl | 184 | 46 |
| Jardiance | Empagliflozin | 177 | 43 |
| Levetiracetam | Levetiracetam | 177 | 35 |
| Tramadol Hcl | Tramadol Hcl | 175 | 56 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 174 | 39 |
| Midodrine Hcl | Midodrine Hcl | 173 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 171 | 45 |
| Nifedipine Er | Nifedipine | 162 | 34 |
| Spironolactone | Spironolactone | 159 | 50 |
| Methocarbamol | Methocarbamol | 157 | 70 |
| Alprazolam | Alprazolam | 156 | 48 |
| Allopurinol | Allopurinol | 155 | 43 |
| Pravastatin Sodium | Pravastatin Sodium | 150 | 37 |
| Alendronate Sodium | Alendronate Sodium | 149 | 35 |
| Nystatin | Nystatin | 149 | 58 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 148 | 58 |
| Prednisone | Prednisone | 148 | 41 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 145 | 44 |
| Finasteride | Finasteride | 144 | 29 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 144 | 38 |
| Latanoprost | Latanoprost | 143 | 30 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 142 | 35 |
| Risperidone | Risperidone | 132 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 130 | 37 |
| Olanzapine | Olanzapine | 128 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 126 | 37 |
| Bumetanide | Bumetanide | 119 | 30 |
| Ondansetron Hcl | Ondansetron Hcl | 118 | 58 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 117 | 38 |
| Paroxetine Hcl | Paroxetine Hcl | 117 | 25 |
| Xarelto | Rivaroxaban | 116 | 25 |
| Hydrocortisone | Hydrocortisone | 112 | 40 |
| Cephalexin | Cephalexin | 111 | 66 |
| Divalproex Sodium | Divalproex Sodium | 105 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 105 | 34 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 105 | 15 |
| Entresto | Sacubitril/Valsartan | 104 | 14 |
| Farxiga | Dapagliflozin Propanediol | 103 | 28 |
| Diclofenac Sodium | Diclofenac Sodium | 97 | 37 |
| Topiramate | Topiramate | 97 | 21 |
| Loperamide | Loperamide Hcl | 96 | 60 |
| Single Use Swab | Alcohol Antiseptic Pads | 96 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 94 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 91 | 36 |
| Ventolin Hfa | Albuterol Sulfate | 90 | 47 |
| Diazepam | Diazepam | 88 | 19 |
| Atenolol | Atenolol | 87 | 24 |
| Incruse Ellipta | Umeclidinium Bromide | 85 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 84 | 28 |
| Ezetimibe | Ezetimibe | 84 | 22 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 83 | 29 |
| Trulicity | Dulaglutide | 81 | 12 |
| Albuterol Sulfate | Albuterol Sulfate | 80 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 79 | 22 |
| Metformin Hcl Er | Metformin Hcl | 76 | 19 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 74 | 17 |
| Clonidine Hcl | Clonidine Hcl | 74 | 17 |
| Bupropion Xl | Bupropion Hcl | 73 | 17 |
| Digoxin | Digoxin | 73 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 72 | 51 |
| Oxybutynin Chloride | Oxybutynin Chloride | 70 | 22 |
| Aripiprazole | Aripiprazole | 69 | 22 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 68 | 25 |
| Ammonium Lactate | Ammonium Lactate | 67 | 22 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 67 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 67 | 21 |
| Januvia | Sitagliptin Phosphate | 67 | 20 |
| Humalog Kwikpen U-100 | Insulin Lispro | 64 | 24 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 63 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 61 | 42 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 61 | 17 |
| Torsemide | Torsemide | 60 | 19 |
| Lactulose | Lactulose | 58 | 17 |
| Levofloxacin | Levofloxacin | 58 | 42 |
| Methylprednisolone | Methylprednisolone | 58 | 45 |
| Meclizine Hcl | Meclizine Hcl | 57 | 16 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 56 | 15 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 55 | 15 |
| Lidocaine | Lidocaine | 54 | 12 |
| Baclofen | Baclofen | 53 | 18 |
| Breo Ellipta | Fluticasone/Vilanterol | 53 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 53 | 14 |
| Myrbetriq | Mirabegron | 53 | 14 |
| Warfarin Sodium | Warfarin Sodium | 52 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 51 | 13 |
| Clonazepam | Clonazepam | 50 | suppressed |
| Ozempic | Semaglutide | 49 | 17 |
| Glipizide | Glipizide | 48 | 16 |
| Benztropine Mesylate | Benztropine Mesylate | 47 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 47 | suppressed |
| Fluconazole | Fluconazole | 44 | 25 |
| Haloperidol | Haloperidol | 43 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 43 | 12 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 42 | 16 |
| Nyamyc | Nystatin | 42 | 17 |
| Pregabalin | Pregabalin | 42 | 17 |
| Symbicort | Budesonide/Formoterol Fumarate | 42 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 42 | 16 |
| Cyclosporine | Cyclosporine | 41 | suppressed |
| Fenofibrate | Fenofibrate | 41 | 12 |
| Promethazine Hcl | Promethazine Hcl | 41 | 18 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 40 | 19 |
| Methenamine Hippurate | Methenamine Hippurate | 40 | suppressed |
| Novolog Flexpen | Insulin Aspart | 40 | 26 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 39 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 39 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 39 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | 11 |
| Glipizide Er | Glipizide | 38 | suppressed |
| Lamotrigine | Lamotrigine | 38 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 37 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 37 | 12 |
| Glimepiride | Glimepiride | 36 | 13 |
| Celecoxib | Celecoxib | 35 | 11 |
| Insulin Aspart Flexpen | Insulin Aspart | 35 | 11 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 34 | 11 |
| Nystop | Nystatin | 34 | 15 |
| Tradjenta | Linagliptin | 34 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 33 | suppressed |
| Verapamil Er | Verapamil Hcl | 33 | suppressed |
| Amoxicillin | Amoxicillin | 32 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 24 |
| Diltiazem Hcl | Diltiazem Hcl | 31 | suppressed |
| Ramipril | Ramipril | 31 | suppressed |
| Synthroid | Levothyroxine Sodium | 31 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 30 | suppressed |
| Metronidazole | Metronidazole | 30 | 11 |
| Chlorthalidone | Chlorthalidone | 29 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 29 | suppressed |
| Enulose | Lactulose | 29 | 13 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 29 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 28 | 12 |
| Folic Acid | Folic Acid | 28 | suppressed |
| Mupirocin | Mupirocin | 28 | 14 |
| Naproxen | Naproxen | 28 | 14 |
| Ondansetron Odt | Ondansetron | 28 | 17 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 28 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 28 | suppressed |
| Tobramycin | Tobramycin | 28 | 19 |
| Zenpep | Lipase/Protease/Amylase | 28 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Gemfibrozil | Gemfibrozil | 27 | suppressed |
| Lansoprazole | Lansoprazole | 27 | suppressed |
| Linzess | Linaclotide | 27 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 27 | suppressed |
| Anastrozole | Anastrozole | 26 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 26 | suppressed |
| Klor-Con M20 | Potassium Chloride | 26 | 14 |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 26 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Calcitriol | Calcitriol | 25 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 25 | suppressed |
| Sucralfate | Sucralfate | 25 | 11 |
| Erythromycin | Erythromycin Base | 24 | 11 |
| Fluphenazine Hcl | Fluphenazine Hcl | 24 | suppressed |
| Ketoconazole | Ketoconazole | 24 | suppressed |
| Klor-Con 10 | Potassium Chloride | 24 | suppressed |
| Methimazole | Methimazole | 24 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 24 | suppressed |
| Cilostazol | Cilostazol | 23 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 13 |
| Diltiazem 24hr Er | Diltiazem Hcl | 22 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 22 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 21 | suppressed |
| Fluphenazine Decanoate | Fluphenazine Decanoate | 21 | suppressed |
| Levemir Flexpen | Insulin Detemir | 21 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 21 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 20 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | 13 |
| Olanzapine Odt | Olanzapine | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 19 | suppressed |
| Gemtesa | Vibegron | 19 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 18 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 18 | suppressed |
| Bicalutamide | Bicalutamide | 17 | suppressed |
| Calcium Acetate | Calcium Acetate | 17 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 17 | suppressed |
| Mirabegron Er | Mirabegron | 17 | suppressed |
| Timolol Maleate | Timolol Maleate | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 16 | suppressed |
| Carbamazepine | Carbamazepine | 16 | suppressed |
| Fentanyl | Fentanyl | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 16 | suppressed |
| Lumigan | Bimatoprost | 16 | suppressed |
| Captopril | Captopril | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 15 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | 12 |
| Creon | Lipase/Protease/Amylase | 14 | suppressed |
| Insulin Lispro | Insulin Lispro | 14 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 14 | suppressed |
| Multaq | Dronedarone Hcl | 14 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 14 | suppressed |
| Trospium Chloride | Trospium Chloride | 14 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 13 | suppressed |
| Lacosamide | Lacosamide | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Pulmicort Flexhaler | Budesonide | 13 | suppressed |
| Aripiprazole Odt | Aripiprazole | 12 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Estarylla | Norgestimate-Ethinyl Estradiol | 12 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 12 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 12 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Tadalafil | Tadalafil | 12 | suppressed |
| Ascomp With Codeine | Codeine/Butalbital/Asa/Caffein | 11 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 11 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 11 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 11 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,787.81 · 72 records | AstraZeneca Pharmaceuticals LP | AFREZZA, AIRSUPRA, AREXVY, BREZTRI, BRIXADI, CAPLYTA, CREXONT, Cologuard Collection Kit, ENTRESTO, JARDIANCE, KISUNLA, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, SUBLOCADE, TRELEGY ELLIPTA, VALTOCO, VRAYLAR, XIFAXAN, ZAVZPRET, ZENPEP, ZEPBOUND, Zubsolv | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Entresto play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error